Skip to Content

MorphoSys AG MPSYF

Morningstar Rating
$70.28 +1.71 (2.50%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MPSYF is trading at a 17% discount.
Price
$70.44
Fair Value
$28.91
Uncertainty
Very High
1-Star Price
$995.28
5-Star Price
$24.15
Economic Moat
Dmqk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MPSYF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$68.57
Day Range
$70.2870.28
52-Week Range
$17.2970.66
Bid/Ask
$68.85 / $72.90
Market Cap
$2.64 Bil
Volume/Avg
100 / 26,074

Key Statistics

Price/Earnings (Normalized)
24.37
Price/Sales
8.62
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
544

Comparables

Valuation

Metric
MPSYF
HPHA
IGMS
Price/Earnings (Normalized)
24.37
Price/Book Value
69.783.232.91
Price/Sales
8.6215.13330.79
Price/Cash Flow
Price/Earnings
MPSYF
HPHA
IGMS

Financial Strength

Metric
MPSYF
HPHA
IGMS
Quick Ratio
3.142.549.01
Current Ratio
3.573.019.27
Interest Coverage
−25.26
Quick Ratio
MPSYF
HPHA
IGMS

Profitability

Metric
MPSYF
HPHA
IGMS
Return on Assets (Normalized)
−28.41%−40.46%
Return on Equity (Normalized)
−55.56%−73.15%
Return on Invested Capital (Normalized)
−41.83%−68.36%
Return on Assets
MPSYF
HPHA
IGMS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRvkk$550.4 Bil
VRTX
Vertex Pharmaceuticals IncGmtrh$111.8 Bil
REGN
Regeneron Pharmaceuticals IncCylwmg$107.9 Bil
MRNA
Moderna IncJzhj$36.3 Bil
ARGX
argenx SE ADRXvc$23.0 Bil
BNTX
BioNTech SE ADRRlgbk$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncFkhzg$19.2 Bil
BMRN
Biomarin Pharmaceutical IncXcvdj$16.4 Bil
RPRX
Royalty Pharma PLC Class ACfvvqty$13.4 Bil
INCY
Incyte CorpCdrxbgr$13.3 Bil

Sponsor Center